Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
MYO vs APVO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
APVO Captures Overall Composite Edge (45.4 HOLD vs 40.1 SELL), While MYO Leads 3–2 on Growth & Valuation Pillars
APVO Overall Winner
6-Pillar Tally: MYO 3 – 2 APVO (1 Tie)
Matrix Metrics: MYO 5 – 5 APVO
As of Nov 20, 2026, Aptevo Therapeutics Inc (APVO) captures the overall head-to-head institutional edge over Myomo Inc. (MYO) on higher Unified Composite conviction (45.4/100 HOLD vs. 40.1/100 SELL) after splitting the core matrix 5–5 (led by Valuation Multiples, Profitability & Quality), while MYO wins 3–2 across the 6-pillar growth and valuation breakdown. MYO trades at $0.81 (N/M Forward P/E, -21.8% operating margin) versus APVO at $0.40 (3.9x Forward P/E, 0.0% operating margin).
- Growth vs. Quality Trade-Off: APVO earns the overall head-to-head edge with a stronger Unified Composite Score (45.4/100 HOLD vs. MYO 40.1/100 SELL) and 0.45β · 121% Vol risk profile, whereas MYO leads top-line expansion (+22.2% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: MYO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.7); meanwhile APVO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 8.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About MYO vs APVO
MYO
Myomo Inc.
$0.81
-3.45% 1D
Market Cap
$33.7M
TTM Revenue
$46M
Forward P/E
N/M
Beta / 30D Vol
2.22β · 107% Vol
Unified Composite Score
40.1
SELL
Tech 25.0
Fund 43.0
Flow 58.0
Mom 59.0
Weinstein Technical Phase
Markdown · Sell / avoid
APVO
Head-to-Head Winner
Aptevo Therapeutics Inc
$0.40
-2.37% 1D
Market Cap
$1.4M
TTM Revenue
N/A
Forward P/E
3.9x
Beta / 30D Vol
0.45β · 121% Vol
Unified Composite Score
45.4
HOLD
Tech 45.0
Fund 44.0
Flow 50.0
Mom 40.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (MYO 3 – 2 APVO)
1. Valuation Multiples
APVO
Forward P/E
N/M
3.9x
Trailing P/E
N/M
0.0x
PEG Ratio
N/M
N/M
EV / Revenue
0.9x
N/M
2. Growth & Scale
MYO
Revenue Growth (YoY)
+22.2%
-100.0%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$46M
N/A
Market Cap
$33.7M
$1.4M
3. Profitability & Quality
APVO
Gross Margin
70.1%
N/A
Operating Margin
-21.8%
0.0%
Net Profit Margin
-33.1%
0.0%
Return on Equity (ROE)
-173.5%
-420.3%
4. Balance Sheet & Cash Flow
MYO
Cash Generation (TTM)
-$9.1M
N/A
Cash Flow Margin
-20.0%
N/A
Net Cash / Leverage
$8.9M Net Debt (3.44x D/E)
$17.42 Book/Sh · -420.3% ROE
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
MYO
Options Structure Phase
UNCLASSIFIED
UNCLASSIFIED
Current IV / %ile
266.0% (81st %ile)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Devices Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: MYO (5) vs APVO (5)| Institutional Metric | MYO | APVO | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $33.7M | $1.4M | MYO | |
| Trailing P/E Ratio | N/M | 0.0x | APVO | |
| Forward P/E Ratio | N/M | 3.9x | APVO | |
| Revenue Growth (YoY) | +22.2% | -100.0% | MYO | |
| Operating Margin (TTM) | -21.8% | 0.0% | APVO | |
| Net Profit Margin | -33.1% | 0.0% | APVO | |
| Return on Equity (ROE) | -173.5% | -420.3% | MYO | |
| 52-Week Range Position | 16% ($1–$2) | 0% ($0–$11) | MYO | |
| Beta / 30D Volatility | 2.22β · 107% Vol | 0.45β · 121% Vol | MYO | |
| Unified Institutional Score | 40.1 / 100 (SELL) | 45.4 / 100 (HOLD) | APVO | |
| Trailing 12M Revenue (USD) | $46M | N/A | Scale | |
| Gross Profit Margin (TTM) | 70.1% | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 0.9x EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$9.1M ($8.9M Net Debt (3.44x D/E)) | N/A ($17.42 Book/Sh · -420.3% ROE) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
MYO +41.38 pp
3M Horizon
MYO +41.58 pp
6M Horizon
MYO +69.82 pp
1Y Horizon
MYO +79.18 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | MYO Revenue | APVO Revenue | MYO Op. Margin | APVO Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $0M | $20M | -430.8% | -224.0% | APVO |
| FY2019 | $0M | $30M | -281.3% | -126.3% | APVO |
| FY2020 | $10M | $0M | -138.5% | -638.1% | MYO |
| FY2021 | $10M | $10M | -74.1% | -174.1% | MYO |
| FY2022 | $20M | $0M | -68.6% | -919.7% | MYO |
| FY2023 | $20M | N/A | -42.8% | N/A | MYO |
| FY2024 | $30M | N/A | -19.1% | N/A | MYO |
| FY2025 | $40M | N/A | -35.2% | N/A | MYO |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
MYO
UNCLASSIFIED
Current IV
266.0%
IV Percentile
81st %ile
Put/Call OI Skew
N/A
IV Regime
Extreme (>80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact MYO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
APVO
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact APVO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
MYO Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
APVO Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ MYO vs APVO Key Questions & Quantitative Answers
As of Nov 20, 2026, Aptevo Therapeutics Inc (APVO) captures the overall head-to-head institutional edge over Myomo Inc. (MYO) on higher Unified Composite conviction (45.4/100 HOLD vs. 40.1/100 SELL) after splitting the core matrix 5–5 (led by Valuation Multiples, Profitability & Quality), while MYO wins 3–2 across the 6-pillar growth and valuation breakdown. MYO trades at $0.81 (N/M Forward P/E, -21.8% operating margin) versus APVO at $0.40 (3.9x Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: APVO earns the overall head-to-head edge with a stronger Unified Composite Score (45.4/100 HOLD vs. MYO 40.1/100 SELL) and 0.45β · 121% Vol risk profile, whereas MYO leads top-line expansion (+22.2% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: MYO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.7); meanwhile APVO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 8.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
MYO leads the Growth & Scale pillar: MYO posts +22.2% YoY revenue growth and +0.0% YoY earnings growth on $46M TTM revenue (70.1% gross margin, -21.8% operating margin), compared with APVO at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), MYO cumulative revenue shifted +300.0% while APVO shifted -50.0%. In operating R&D and SG&A reinvestment, MYO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for APVO.
APVO screens cheaper on headline valuation multiples. MYO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.9x EV/Revenue (-20.0% FCF margin), whereas APVO trades at 3.9x Forward P/E, 0.0x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MYO (-173.5% ROE) versus APVO (-420.3% ROE) capital efficiency.
In options market volatility and institutional positioning, MYO carries 266.0% implied volatility (81st %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.22β · 107% Vol realized risk). By comparison, APVO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.45β · 121% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
APVO vs MYO · Reverse Pair
APVO vs KZIA
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking
VRT vs ETN
· AI Power & Thermal